Director of Bio Farma Honesti Basyir confirmed that the price of the Covid-19 vaccine will be around Rp. 200,000.
The statement was in response to the news regarding the Sinovac agreement with Brazil, with the vaccine price of approximately US $ 1.96 per dose or the equivalent of Rp. 29,000 (at an exchange rate of Rp.14,764 per US dollar).
However, Sinovac has disputed this price through an official letter sent to Bio Farma.
“The price range is around IDR 200,000. We have clarified the information on the price of the Covid-19 vaccine in Brazil to Sinovac. They have sent an official e-mail to Bio Farma, which ensures that the information in the news about the purchase contract for 46 million doses with a contract value of US$ 90 million with the Brazilian government is not accurate. Regarding the price of US$ 1.96 per dose, it is not correct,” Honesti said in an official statement on Tuesday (13/10).
According to Honesti, the shipping cost for each dose is around US$ 2. Honesti revealed that in the official letter sent by Sinovac, there are several factors that determine the price of the Covid-19 vaccine. One factor hinges on investments in phase 3 clinical studies, especially on large-scale efficacy trials.
Likewise, pricing in Indonesia shall be determined by the same factors. In other words, the Covid-19 vaccine pricing scheme cannot be equated.
Honesti explained that to maintain and guarantee the quality of the Covid-19 vaccine, starting from raw materials and others factors, the Food and Drug Administration (BPOM) will visit China to perform an audit of the development and production process of the Covid-19 vaccine at the Sinovac facility in Beijing.
The Institute for the Study of Food, Drugs and Cosmetics, the Indonesian Ulema Council (LPPOM MUI/ Indonesia’s top Muslim clerical body) will be involved to carry out a halal audit. The BPOM will also ensure that the facilities and production processes for the Covid-19 vaccine at Bio Farma meet the standards for Good Manufacturing Practices (GMP).
At present, the phase 3 clinical trial of the Covid-19 vaccine is still ongoing as of the second week of October 2020.
The latest data shows that as of October 9, 2020, 843 volunteers have received the second injection, and 449 volunteers are in the blood collection stage after the second injection and are entering the monitoring period.
To date, the Phase 3 Clinical Trial is running smoothly and there have been no reports of serious Post-Immunization Follow-Up incidents due to the injection of the Covid-19 vaccine candidate.